Cargando…
(18)F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab
PURPOSE: We evaluated the prognostic value of (18)F-sodium fluoride (NaF) PET/CT in patients with urological malignancies treated with cabozantinib and nivolumab with or without ipilimumab. METHODS: We prospectively recruited patients with advanced urological malignancies into a phase I trial of cab...
Autores principales: | Lim, Ilhan, Lindenberg, Maria Liza, Mena, Esther, Verdini, Nicholas, Shih, Joanna H., Mayfield, Christian, Thompson, Ryan, Lin, Jeffrey, Vega, Andy, Mallek, Marissa, Cadena, Jacqueline, Diaz, Carlos, Mortazavi, Amir, Knopp, Michael, Wright, Chadwick, Stein, Mark, Pal, Sumanta, Choyke, Peter L., Apolo, Andrea B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885023/ https://www.ncbi.nlm.nih.gov/pubmed/31522271 http://dx.doi.org/10.1007/s00259-019-04483-5 |
Ejemplares similares
-
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020) -
Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021) -
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021) -
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
por: Girardi, Daniel M., et al.
Publicado: (2022)